ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $637,231 | -91.5% | 13,698 | -92.3% | 0.00% | -93.9% |
| Q4 2020 | $7,464,000 | -30.3% | 177,288 | -24.2% | 0.03% | -21.4% |
| Q3 2020 | $10,704,000 | +25.2% | 233,820 | +37.3% | 0.04% | -2.3% |
| Q2 2020 | $8,551,000 | -15.4% | 170,324 | -13.4% | 0.04% | -34.8% |
| Q1 2020 | $10,111,000 | -45.5% | 196,605 | -34.5% | 0.07% | +8.2% |
| Q4 2019 | $18,540,000 | +4.3% | 300,085 | +1.4% | 0.06% | -7.6% |
| Q3 2019 | $17,781,000 | +100.3% | 295,954 | +181.3% | 0.07% | +106.2% |
| Q2 2019 | $8,878,000 | +30.7% | 105,211 | +48.0% | 0.03% | +23.1% |
| Q1 2019 | $6,792,000 | +198.8% | 71,111 | +121.6% | 0.03% | +160.0% |
| Q4 2018 | $2,273,000 | -61.1% | 32,088 | -53.1% | 0.01% | -52.4% |
| Q3 2018 | $5,847,000 | -60.7% | 68,417 | -46.7% | 0.02% | -65.6% |
| Q2 2018 | $14,872,000 | -33.3% | 128,317 | -53.5% | 0.06% | -40.2% |
| Q1 2018 | $22,310,000 | – | 275,742 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |